期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 12, 期 3, 页码 363-370出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2012.658770
关键词
biological therapy; certolizumab pegol; Crohn's disease; inflammatory bowel disease; TNF alpha inhibitor
资金
- Pfizer
- Salix Pharmaceuticals
- Millenium Pharmaceuticals
- Prometheus Laboratories
- GSK
- Abbott Pharmaceuticals
- UCB Pharma
- Centocor Inc.
Introduction: Crohn's disease (CD) is a chronic, idiopathic, inflammatory bowel disease with no known cure. In those patients with moderate to severe disease, the result is often a clinically debilitating condition. In the last decade, one of the most significant developments in therapy has been a class of biological agents that neutralize TNF alpha. Certolizumab pegol (CZP) is the most recently FDA approved anti-TNF agent for the induction and maintenance of moderate to severely active Crohn's disease. Areas covered: The currently available evidence regarding the use of CZP in CD, the expected efficacy and possible adverse events associated with this population. Expert opinion: CZP is a TNFa inhibitor that is a safe and effective agent for treatment of CD. It has several unique features which make it useful in patients with moderate to severe disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据